These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 18175394)

  • 41. Genetics of Parkinson's disease.
    Bonifati V
    Minerva Med; 2005 Jun; 96(3):175-86. PubMed ID: 16175160
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diagnosis and treatment of Parkinson disease: molecules to medicine.
    Savitt JM; Dawson VL; Dawson TM
    J Clin Invest; 2006 Jul; 116(7):1744-54. PubMed ID: 16823471
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Novel cell death signaling pathways in neurotoxicity models of dopaminergic degeneration: relevance to oxidative stress and neuroinflammation in Parkinson's disease.
    Kanthasamy A; Jin H; Mehrotra S; Mishra R; Kanthasamy A; Rana A
    Neurotoxicology; 2010 Sep; 31(5):555-61. PubMed ID: 20005250
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Proteasomal inhibition hypersensitizes differentiated neuroblastoma cells to oxidative damage.
    Lev N; Melamed E; Offen D
    Neurosci Lett; 2006 May; 399(1-2):27-32. PubMed ID: 16584840
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oxidative stress and genetics in the pathogenesis of Parkinson's disease.
    Zhang Y; Dawson VL; Dawson TM
    Neurobiol Dis; 2000 Aug; 7(4):240-50. PubMed ID: 10964596
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dynamic modeling of alpha-synuclein aggregation for the sporadic and genetic forms of Parkinson's disease.
    Raichur A; Vali S; Gorin F
    Neuroscience; 2006 Oct; 142(3):859-70. PubMed ID: 16920272
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pathogenesis of Parkinson's disease.
    Sherer TB; Betarbet R; Greenamyre JT
    Curr Opin Investig Drugs; 2001 May; 2(5):657-62. PubMed ID: 11569943
    [TBL] [Abstract][Full Text] [Related]  

  • 48. What causes cell death in Parkinson's disease?
    Gupta A; Dawson VL; Dawson TM
    Ann Neurol; 2008 Dec; 64 Suppl 2(0 2):S3-15. PubMed ID: 19127586
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impairment of proteasome and anti-oxidative pathways in the induced pluripotent stem cell model for sporadic Parkinson's disease.
    Chang KH; Lee-Chen GJ; Wu YR; Chen YJ; Lin JL; Li M; Chen IC; Lo YS; Wu HC; Chen CM
    Parkinsonism Relat Disord; 2016 Mar; 24():81-8. PubMed ID: 26797011
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neurodegenerative pathways in Parkinson's disease: therapeutic strategies.
    Cardoso SM; Moreira PI; Agostinho P; Pereira C; Oliveira CR
    Curr Drug Targets CNS Neurol Disord; 2005 Aug; 4(4):405-19. PubMed ID: 16101557
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bioenergetic and proteolytic defects in fibroblasts from patients with sporadic Parkinson's disease.
    Ambrosi G; Ghezzi C; Sepe S; Milanese C; Payan-Gomez C; Bombardieri CR; Armentero MT; Zangaglia R; Pacchetti C; Mastroberardino PG; Blandini F
    Biochim Biophys Acta; 2014 Sep; 1842(9):1385-94. PubMed ID: 24854107
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Parkinson's disease: a short story of 200 years.
    Cuenca L; Gil-Martinez AL; Cano-Fernandez L; Sanchez-Rodrigo C; Estrada C; Fernandez-Villalba E; Herrero MT
    Histol Histopathol; 2019 Jun; 34(6):573-591. PubMed ID: 30540129
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Brain aging and Parkinson's disease: New therapeutic approaches using drug delivery systems.
    Rodríguez-Nogales C; Garbayo E; Carmona-Abellán MM; Luquin MR; Blanco-Prieto MJ
    Maturitas; 2016 Feb; 84():25-31. PubMed ID: 26653838
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Heat shock protein 90 modulates LRRK2 stability: potential implications for Parkinson's disease treatment.
    Hurtado-Lorenzo A; Anand VS
    J Neurosci; 2008 Jul; 28(27):6757-9. PubMed ID: 18596151
    [No Abstract]   [Full Text] [Related]  

  • 55. Measurement of proteasomal dysfunction in cell models of dopaminergic degeneration.
    Sun F; Kanthasamy AG; Kanthasamy A
    Methods Mol Biol; 2011; 758():293-305. PubMed ID: 21815074
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Disruption of protein quality control in Parkinson's disease.
    Cook C; Stetler C; Petrucelli L
    Cold Spring Harb Perspect Med; 2012 May; 2(5):a009423. PubMed ID: 22553500
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Parkinson's disease: oxidative stress and therapeutic approaches.
    Surendran S; Rajasankar S
    Neurol Sci; 2010 Oct; 31(5):531-40. PubMed ID: 20221655
    [TBL] [Abstract][Full Text] [Related]  

  • 58. What causes the build-up of ubiquitin-containing inclusions in Parkinson's disease?
    Andersen JK
    Mech Ageing Dev; 2000 Sep; 118(1-2):15-22. PubMed ID: 10989121
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps.
    Levy OA; Malagelada C; Greene LA
    Apoptosis; 2009 Apr; 14(4):478-500. PubMed ID: 19165601
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inflammatory and cell death pathways in brain and peripheral blood in Parkinson's disease.
    Macchi B; Di Paola R; Marino-Merlo F; Felice MR; Cuzzocrea S; Mastino A
    CNS Neurol Disord Drug Targets; 2015; 14(3):313-24. PubMed ID: 25714978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.